

 Open access • Posted Content • DOI:10.1101/2021.01.28.21250606

REACT-1 round 8 final report: high average prevalence with regional heterogeneity of trends in SARS-CoV-2 infection in the community in England during January 2021

— [Source link](#) 

[Steven Riley](#), [Oliver Eales](#), [Caroline E. Walters](#), [Haowei Wang](#) ...+18 more authors

Institutions: [Imperial College London](#), [Lancaster University](#), [University of Oxford](#), [Imperial College Healthcare](#) ...+1 more institutions

Published on: 31 Jan 2021 - [medRxiv](#) (Cold Spring Harbor Laboratory)

Topics: [Population](#)

Related papers:

- [Prevalence of life limiting illness in children and young people in the UK](#)
- [A nationwide analysis of population group differences in the COVID-19 epidemic in Israel, February 2020–February 2021](#)
- [Area-level indicators of income and total mortality during the COVID-19 pandemic.](#)
- [High excess mortality in areas with young and socially vulnerable populations during the COVID-19 outbreak in Stockholm Region, Sweden.](#)
- [Urban environments and COVID-19 in three Eastern states of the United States.](#)

Share this paper:    

View more about this paper here: <https://typeset.io/papers/react-1-round-8-final-report-high-average-prevalence-with-3714a84e7n>

REACT-1 round 8 final report: high average prevalence with regional heterogeneity of trends in SARS-CoV-2 infection in the community in England during January 2021

Steven Riley^{1,2,*}, Oliver Eales^{1,2}, Caroline E. Walters^{1,2}, Haowei Wang^{1,2}, Kylie E. C. Ainslie^{1,2,12}, Christina Atchison¹, Claudio Fronterre³, Peter J. Diggle³, Deborah Ashby¹, Christl A. Donnelly^{1,2,4}, Graham Cooke^{5,6,7}, Wendy Barclay⁵, Helen Ward^{1,6,7}, Ara Darzi^{6,7,8}, Paul Elliott^{1,6,7,9,10,11 *}

¹ School of Public Health, Imperial College London, UK

² MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency Analytics, Imperial College London, UK

³ CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK

⁴ Department of Statistics, University of Oxford, UK

⁵ Department of Infectious Disease, Imperial College London, UK

⁶ Imperial College Healthcare NHS Trust, UK

⁷ National Institute for Health Research Imperial Biomedical Research Centre, UK

⁸ Institute of Global Health Innovation at Imperial College London, UK

⁹ MRC Centre for Environment and Health, School of Public Health, Imperial College London, UK

¹⁰ Health Data Research (HDR) UK London at Imperial College

¹¹ UK Dementia Research Institute at Imperial College

¹² Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands

*Corresponding authors: Steven Riley and Paul Elliott, s.riley@imperial.ac.uk, p.elliott@imperial.ac.uk, School of Public Health, Imperial College London, Norfolk Place, London, W2 1PG

Abstract

In early January 2021, England entered its third national lockdown of the COVID-19 pandemic to reduce numbers of deaths and pressure on healthcare services, while rapidly rolling out vaccination to healthcare workers and those most at risk of severe disease and death. REACT-1 is a survey of SARS-CoV-2 prevalence in the community in England, based on repeated cross-sectional samples of the population. Between 6th and 22nd January 2021, out of 167,642 results, 2,282 were positive giving a weighted national prevalence of infection of 1.57% (95% CI, 1.49%, 1.66%). The R number nationally over this period was estimated at 0.98 (0.92, 1.04). Prevalence remained high throughout, but with suggestion of a decline at the end of the study period. The average national trend masked regional heterogeneity, with robustly decreasing prevalence in one region (South West) and increasing prevalence in another (East Midlands). Overall prevalence at regional level was highest in London at 2.83% (2.53%, 3.16%). Although prevalence nationally was highest in the low-risk 18 to 24 year old group at 2.44% (1.96%, 3.03%), it was also high in those over 65 years who are most at risk, at 0.93% (0.82%, 1.05%). Large household size, living in a deprived neighbourhood, and Black and Asian ethnicity were all associated with higher levels of infections compared to smaller households, less deprived neighbourhoods and other ethnicities. Healthcare and care home workers, and other key workers, were more likely to test positive compared to other workers. If sustained lower prevalence is not achieved rapidly in England, pressure on healthcare services and numbers of COVID-19 deaths will remain unacceptably high.

Introduction

REACT-1 is a community survey of SARS-CoV-2 prevalence in England, based on repeated non-overlapping cross-sectional surveys of random samples of the population [1]. At each round, we collect self-administered throat and nose swabs and questionnaire data from between 120,000 and 180,000 people ages 5 years and above, over a period of ~17 days, at approximately monthly intervals. Importantly, unlike the routine testing of symptomatic individuals, we include swabs irrespective of whether participants report symptoms, so as to estimate community-wide prevalence unbiased by testing availability or behaviour.

We have previously reported that prevalence of infection in early to mid January 2021 was the highest since the start of the REACT-1 programme in May 2020, towards the end of the first lockdown in England [2]. The high and rapidly increasing prevalence in the second wave appears partly to be due to the emergence of a more transmissible strain of SARS-CoV-2 that was first observed in southern England in September 2020 [3,4]. Our previous report mainly covered the period from 6th to 15th January 2021 during the first part of round 8 of the REACT-1 study, coinciding with implementation of a third national lockdown in England. Here we report results for the whole of round 8 from 6th to 22nd January 2021, and compare our findings with the positivity rate of swabs reported through routine surveillance of symptomatic individuals.

Results and Discussion

We found 2,282 positives from 167,642 valid swabs in round 8 giving a weighted prevalence of 1.57% (95% CI, 1.49%, 1.66%) (Table 1). With a constant growth model, we found no strong evidence for either growth or decay averaged over the period between 6th to 22nd January 2021¹ (Table 2, Figure 1). Over this period, we estimated R at 0.98 (0.92, 1.04) within the round, with weak evidence for non-constant growth: a logistic regression model with a smooth term gave Δ AIC ~4 compared with one using only a constant term. Fitting a p-spline suggested prevalence was approximately constant or increasing slightly from 6th to 15th January, as previously reported [2], but may have then started to decline (Figure 2).

Mobility data from the Facebook app suggest that there was a marked decrease in activity over the Christmas period and at the end of December 2020, followed by a rise in early January 2021 (Figure 3). These mobility patterns may help explain why there was an apparent fall in prevalence from a peak in late December 2020 observed by the Office for National Statistics Coronavirus Infection Survey (ONS-CIS) [5] (when REACT-1 was not collecting data). Compared with the first national lockdown, the absence of a sharp decline

¹ includes 2,229 swabs collected from 30th December 2020 to 5th January 2021

in prevalence during the third lockdown may be explained by a combination of: higher average levels of mobility; more people allowed to physically attend their workplace; a larger number of children eligible to attend school [6]; and a higher intrinsic transmissibility of the new variant [3,4]. We note that although there is suggestion in our data of a decline in prevalence since the 16th January, this would not be explained by patterns in the Facebook mobility data which have remained constant since early January. Rather, it may be due to the end of a temporary increase in household transmission driven by the start of lockdown, given that there is a higher prevalence of infection in people living in larger households (see below). The apparent recent decline may also reflect changing patterns of social interactions during lockdown.

Regional p-splines suggest that the national average trend may mask differences in trends at the regional level (Table 3, Figure 4). Specifically, there was evidence of decline in South West, and suggestion of a decline in London and South East during the latter part of round 8. In contrast, there is evidence of an increase in prevalence in East Midlands with suggestion of increases in West Midlands and Yorkshire and The Humber. Such differences in regional trends may have contributed to higher levels of volatility in national data during previous periods of high prevalence in this pandemic [7], as they do during seasonal influenza epidemics [8]. Trends in the highest prevalence regions will have the greatest impact on the national average.

Regional patterns of prevalence estimated for this round of REACT-1 share key features with regional patterns of PCR-positivity from routine surveillance data [9] (Figure 5). Both data streams appear to be declining in North West, South West, London and South East. Both appear to be either level or increasing in the remaining regions. Also, in the routine surveillance data, all regions show a clear inflection point in early January which is consistent with either a plateau or substantial reduction in the rate of decline of prevalence at the time of the New Year increase in mobility (Figure 3). PCR-positivity may better reveal underlying infection patterns than case counts [9] during periods when care-seeking behaviour is changing, as has been seen in models of influenza transmission [10].

As a sensitivity analysis, we filtered the posterior distribution of prevalence trajectories, keeping only those that were consistent with the ONS-CIS estimated prevalence of 2.06% in the last 5 days of December [5] (Figure 6). This constraint did not materially affect the shape of the p-splines from January 6th, suggesting that the shape of the p-spline was robust to the absence of observations in our study during the late December 2020 peak when REACT-1 was not in the field.

As well as investigating trends in prevalence we undertook analyses of regional and socio-demographic variables that may be associated with increased odds of infection (Table 4, Figure 7). Regional prevalence was highest in London at 2.83% (2.53%, 3.16%), with prevalence greater than 2% in those aged 55 to 64 and those 65 years and over, and over 4% in those aged 13 to 17 and 18 to 24 years (Figure 8). This reflects the rapid increase in prevalence in London and surrounding areas in East of England and South East (Essex and Kent) that we first detected in early December 2020 [7].

Risk of severe disease and death from SARS-CoV-2 infection is correlated strongly with increasing age [11]. Prevalence nationally was highest in 18 to 24 year olds with a weighted prevalence of 2.44% (1.96%, 3.03%), and was as high as 0.93% (0.82%, 1.05%) in those aged 65 and over (Figure 9). Previous reports have highlighted the role of transmission at younger ages [12] that has then fed through into increasing rates at older ages where people are more likely to present with severe disease.

Large household size, living in a deprived neighbourhood, and Black and Asian ethnicity were all associated with increased prevalence (Table 4). There was a monotonic increase in prevalence from the smallest to the largest households rising from 1.24% (1.06%, 1.44%) in single-person households to 3.05% (2.04%, 4.56%) in households of seven or more people. People living in neighbourhoods in the two most deprived quintiles had prevalence of 1.79% (1.53%, 2.10%) and 1.95% (1.74%, 2.19%) compared with 1.22% (1.10%, 1.35%) for those in the least deprived. Participants of Black and Asian ethnicity had increased prevalence at 3.07% (2.29%, 4.09%) and 2.80% (2.32%, 3.37%) respectively compared with 1.41% (1.33%, 1.49%) among white participants. This is similar to data from antibody testing, indicating higher risk of infection among these minority ethnic groups [13]. Differences in prevalence for these variables were reflected in elevated odds ratios within a jointly adjusted logistic regression model (Table 5, Figure 10).

Both healthcare and care home workers, and other key workers, had increased odds of swab-positivity compared to other workers at 1.48 (1.25, 1.77) and 1.35 (1.20, 1.51) respectively (Table 5, Figure 10). Health care and care home workers had over five-fold odds of infection compared with other workers at the end of the first wave [14], indicating the importance of nosocomial infections in driving the epidemic at that time. This category and other key workers continue to have higher prevalence of infection than other workers which likely reflects higher occupational exposure to the virus.

We used a nearest-neighbours statistic to generate a smoothed prevalence map for round 8 at the level of lower-tier local authority (LTLA) (Figure 11). We observed marked

heterogeneity with highest prevalence in London and a contiguous area radiating out into East of England and South East. There were also pockets of high prevalence in West Midlands and other regions.

Conclusions

In this large study of SARS-CoV-2 prevalence in the community in England, we show that prevalence in January 2021 nationally was at extremely high levels. This is being reflected in high levels of hospital admissions, intensive care admission and deaths [9]. While there was indication of a possible decline in prevalence toward the end of our study period (up to 22nd January), the levels of infection remain much higher than those seen during lockdown in May 2020 [14], with a shallower downward trajectory. Unless the prevalence of infection in the community can be lowered substantially, the extreme pressure on health services will continue over the coming weeks, and possibly months, until the vaccination programme protects sufficient numbers of at-risk individuals. In the meantime, it is essential that we continue to observe public health measures to contain the virus including social distancing, face covers, hand-washing and isolation of cases.

Methods

REACT-1 methods are published [1]. At each round, we collect questionnaire data and self-administered throat and nose swabs (using dry swabs) which are sent at 4⁰ to 8⁰C to a single laboratory for RT-PCR. We obtain the sample from the list of National Health Service patients, selected randomly and stratified at LTLA level (n=315) to give approximately equal numbers for each LTLA.

In round 8, we sent out 761,007 registration letters to named individuals, of whom 213,746 (28.1%) registered (parent/guardian for children ages 5 to 12 years); swabs from 168,988 (79.1%) people were returned of which 1,346 (0.8%) had an invalid RT-PCR result. That left 167,642 returned swabs with a valid result, giving an overall response rate (valid swabs divided by total number of people invited) of 22.0%.

We obtain unweighted prevalence estimates from the counts of swab-positivity (based on RT-PCR) compared with the number of swabs returned; we also calculate prevalence estimates weighted to be representative of the population of England as a whole, based on age, sex, region and ethnicity. We estimate prevalence by socio-demographic and other characteristics and use multivariable logistic regression to obtain jointly adjusted estimates of the odds of swab-positivity.

Per round, we use exponential growth models to estimate time trends and reproduction number R , nationally and regionally, and obtain smoothed within-round prevalence estimates using a p-spline function with knots at 5-day intervals [15]. We evaluate geographic variation in prevalence by LTLA using a neighbourhood spatial smoothing method based on nearest neighbour up to 30 km as previously described [16].

We carry out a range of sensitivity analyses including estimation of R for different cut-points for CT values that determine swab-positivity and for non-symptomatic individuals (not reporting symptoms on the day of swab or week prior). We also compare data from the national routine programme of symptomatic testing [9] with our own data at regional level.

Statistical analyses are carried out in R [17]. We obtained research ethics approval from the South Central-Berkshire B Research Ethics Committee (IRAS ID: 283787).

References

1. Riley S, Atchison C, Ashby D, Donnelly CA, Barclay W, Cooke G, et al. REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol. Wellcome Open Research. 2020. p. 200. doi:10.12688/wellcomeopenres.16228.1
2. Riley S, Wang H, Eales O, Walters CE, Ainslie KEC, Atchison C, et al. REACT-1 round 8 interim report: SARS-CoV-2 prevalence during the initial stages of the third national lockdown in England. doi:10.1101/2021.01.20.21250158
3. Davies NG, Barnard RC, Jarvis CI, Kucharski AJ, Munday J, Pearson CAB, et al. Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. bioRxiv. medRxiv; 2020. doi:10.1101/2020.12.24.20248822
4. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. bioRxiv. medRxiv; 2021. doi:10.1101/2020.12.30.20249034
5. Office for National Statistics. Coronavirus (COVID-19) Infection Survey, UK: 8 January 2021. Office for National Statistics; 2021 Aug. Available: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveyspilot/8january2021>
6. Cabinet Office UK Government. National lockdown: Stay at Home. In: gov.uk [Internet]. 1 Apr 2021 [cited 19 Jan 2021]. Available: <https://www.gov.uk/guidance/national-lockdown-stay-at-home>
7. Riley S, Walters CE, Wang H, Eales O, Ainslie KEC, Atchinson C, et al. REACT-1 round 7 updated report: regional heterogeneity in changes in prevalence of SARS-CoV-2 infection during the second national COVID-19 lockdown in England. doi:10.1101/2020.12.15.20248244
8. Ben-Nun M, Riley P, Turtle J, Bacon DP, Riley S. Forecasting national and regional influenza-like illness for the USA. PLoS Comput Biol. 2019;15: e1007013.

9. UK Government. UK government Covid-19 dashboard. In: UK government Covid-19 dashboard [Internet]. Available: <https://coronavirus.data.gov.uk/>
10. Dorigatti I, Cauchemez S, Ferguson NM. Increased transmissibility explains the third wave of infection by the 2009 H1N1 pandemic virus in England. *Proc Natl Acad Sci U S A*. 2013;110: 13422–13427.
11. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. *Lancet Infect Dis*. 2020. doi:10.1016/S1473-3099(20)30243-7
12. Riley S, Ainslie KEC, Eales O, Walters CE, Wang H, Atchison C, et al. High prevalence of SARS-CoV-2 swab positivity and increasing R number in England during October 2020: REACT-1 round 6 interim report. *Infectious Diseases (except HIV/AIDS)*. medRxiv; 2020. doi:10.1101/2020.10.30.20223123
13. Ward H, Atchison CJ, Whitaker M, Ainslie KEC, Elliott J, Okell LC, et al. Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults. *Nature Communications (In press)*. 2020. doi:10.37473/dac/10.1101/2020.08.12.20173690
14. Riley S, Ainslie KEC, Eales O, Jeffrey B, Walters CE, Atchison CJ, et al. Community prevalence of SARS-CoV-2 virus in England during May 2020: REACT study. *Infectious Diseases (except HIV/AIDS)*. medRxiv; 2020. doi:10.1101/2020.07.10.20150524
15. Lang S, Brezger A. Bayesian P-Splines. *J Comput Graph Stat*. 2004;13: 183–212.
16. Riley S, Ainslie KEC, Eales O, Walters CE, Wang H, Atchison C, et al. REACT-1 round 6 updated report: high prevalence of SARS-CoV-2 swab positivity with reduced rate of growth in England at the start of November 2020. *Infectious Diseases (except HIV/AIDS)*. medRxiv; 2020. p. 200. doi:10.1101/2020.11.18.20233932
17. R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2020. Available: <https://www.R-project.org/>

Data availability

Supporting data for tables and figures are available either: in this Google [spreadsheet](#); or in the inst/extdata directory of this [GitHub R package](#).

Declaration of interests

We declare no competing interests.

Funding

The study was funded by the Department of Health and Social Care in England.

Acknowledgements

SR, CAD acknowledge support: MRC Centre for Global Infectious Disease Analysis, National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU), Wellcome Trust (200861/Z/16/Z, 200187/Z/15/Z), and Centres for Disease Control and

Prevention (US, U01CK0005-01-02). GC is supported by an NIHR Professorship. PE is Director of the MRC Centre for Environment and Health (MR/L01341X/1, MR/S019669/1). PE acknowledges support from Health Data Research UK (HDR UK); the NIHR Imperial Biomedical Research Centre; NIHR HPRUs in Chemical and Radiation Threats and Hazards, and Environmental Exposures and Health; the British Heart Foundation Centre for Research Excellence at Imperial College London (RE/18/4/34215); and the UK Dementia Research Institute at Imperial (MC_PC_17114). We thank The Huo Family Foundation for their support of our work on COVID-19.

We thank key collaborators on this work – Ipsos MORI: Kelly Beaver, Sam Clemens, Gary Welch, Nicholas Gilby, Kelly Ward and Kevin Pickering; Institute of Global Health Innovation at Imperial College: Gianluca Fontana, Dr Hutan Ashrafian, Sutha Satkunarajah, Didi Thompson and Lenny Naar; Molecular Diagnostic Unit, Imperial College London: Prof. Graham Taylor; North West London Pathology and Public Health England for help in calibration of the laboratory analyses; NHS Digital for access to the NHS register; and the Department of Health and Social Care for logistic support. SR acknowledges helpful discussion with attendees of meetings of the UK Government Office for Science (GO-Science) Scientific Pandemic Influenza – Modelling (SPI-M) committee.

Tables and Figures

Table 1. Unweighted and weighted prevalence of swab-positivity across eight rounds of REACT-1.

Round	Tested swabs	Positive swabs	Unweighted prevalence (95% CI)	Weighted prevalence (95% CI)	First sample	Last sample
1	120,620	159	0.13% (0.11%, 0.15%)	0.16% (0.13%, 0.19%)	1/5/2020	1/6/2020
2	159,199	123	0.077% (0.065%, 0.092%)	0.088% (0.068%, 0.11%)	19/6/2020	7/7/2020
3	162,821	54	0.033% (0.025%, 0.043%)	0.040% (0.027%, 0.053%)	24/7/2020	11/8/2020
4	154,325	137	0.089% (0.075%, 0.11%)	0.13% (0.096%, 0.15%)	20/8/2020	8/9/2020
5	174,949	824	0.47% (0.44%, 0.50%)	0.60% (0.55%, 0.71%)	18/9/2020	5/10/2020
6	160,175	1,732	1.08% (1.03%, 1.13%)	1.30% (1.21%, 1.39%)	16/10/2020	2/11/2020
6a	85,965	863	1.00% (0.94%, 1.07%)	1.28% (1.16%, 1.42%)	16/10/2020	25/10/2020
6b	74,210	869	1.17% (1.10%, 1.25%)	1.32% (1.20%, 1.45%)	26/10/2020*	2/11/2020
7	168,181	1,299	0.77% (0.73%, 0.82%)	0.94% (0.87%, 1.01%)	13/11/2020	3/12/2020
7a	105,122	821	0.78% (0.73%, 0.84%)	0.96% (0.87%, 1.05%)	13/11/2020	24/11/2020
7b	63,059	478	0.76% (0.69%, 0.83%)	0.91% (0.81%, 1.03%)	25/11/2020*	3/12/2020
8	167,642	2,282	1.36% (1.31%, 1.42%)	1.57% (1.49%, 1.66%)	06/01/2021**	22/01/2021

* Includes some samples from prior period

** Includes some swab tests from 30th December onwards

Table 2. Estimates of national growth rates, doubling times and reproduction numbers for round 8 .

Round	Outcome	Growth rate	R*	Probability R>1	Number of Positives
8	All positives	-0.003 (-0.014 , 0.007)	0.98 (0.92 , 1.04)	0.27	2253**
	Non-symptomatics	-0.012 (-0.031 , 0.006)	0.92 (0.81 , 1.04)	0.10	742
	Positive for both E and N genes	-0.007 (-0.020 , 0.006)	0.95 (0.88 , 1.04)	0.13	1476
	Positive for both E and N genes or positive only for N gene with CT 35 or less	-0.007 (-0.019 , 0.004)	0.95 (0.89 , 1.02)	0.09	1946
	Positive for both E and N genes or positive only for N gene with CT 30 or less	-0.007 (-0.020 , 0.006)	0.96 (0.88 , 1.04)	0.13	1491
	Positive for both E and N genes or positive only for N gene with CT 27 or less	-0.007 (-0.020 , 0.006)	0.96 (0.88 , 1.04)	0.14	1477

* Doubling/Halving time not shown because R close to 1

** Discrepancy with numbers in table 1 due to positives missing a date variable not being included in the analysis

Table 3. Estimates of regional growth rates, doubling times and reproduction numbers for round 8.

Round	Region	Growth rate		R	Probability R>1	Halving (-) / Doubling (+) time
8	East Midlands	0.030	(-0.003 , 0.063)	1.20 (0.98 , 1.45)	0.96	22.8 (* , 11.0)
	West Midlands	0.009	(-0.026 , 0.044)	1.06 (0.84 , 1.30)	0.70	* (-26.7 , 15.8)
	East of England	-0.003	(-0.028 , 0.022)	0.98 (0.83 , 1.14)	0.41	* (-24.6 , 32.1)
	London	-0.005	(-0.028 , 0.016)	0.97 (0.83 , 1.11)	0.32	* (-24.9 , 42.3)
	North West	-0.009	(-0.045 , 0.025)	0.94 (0.74 , 1.16)	0.30	* (-15.4 , 28.0)
	North East	0.005	(-0.057 , 0.063)	1.03 (0.67 , 1.45)	0.56	* (-12.1 , 11.0)
	South East	-0.012	(-0.034 , 0.009)	0.92 (0.80 , 1.06)	0.13	* (-20.4 , *)
	South West	-0.082	(-0.129 , -0.037)	0.55 (0.36 , 0.78)	<0.01	-8.5 (-5.4 , -18.8)
	Yorkshire **	0.014	(-0.040 , 0.063)	1.09 (0.76 , 1.45)	0.70	49.8 (-17.3 , 11.0)

* Doubling/Halving time had an estimated magnitude greater than 50 days and so represented approximately constant prevalence.

** Yorkshire and The Humber

Table 4. Unweighted and weighted prevalence of swab-positivity for round 8.

Variable	Category	Round 8			
		Positive	Total	Unweighted Prevalence	Weighted Prevalence
Gender	Male	1043	75,296	1.39% (1.30% , 1.47%)	1.63% (1.50% , 1.77%)
	Female	1239	92,340	1.34% (1.27% , 1.42%)	1.51% (1.41% , 1.63%)
	NA	0	6	0.00% (0.00% , 31.08%)	0.00% (NA , NA)
Age	05-12	170	11,727	1.45% (1.25% , 1.68%)	1.59% (1.32% , 1.93%)
	13-17	172	8,947	1.92% (1.66% , 2.23%)	2.25% (1.85% , 2.73%)
	18-24	156	6,753	2.31% (1.98% , 2.70%)	2.44% (1.96% , 3.03%)
	25-34	263	15,031	1.75% (1.55% , 1.97%)	1.95% (1.68% , 2.26%)
	35-44	314	21,764	1.44% (1.29% , 1.61%)	1.62% (1.41% , 1.85%)
	45-54	412	27,982	1.47% (1.34% , 1.62%)	1.61% (1.43% , 1.81%)
	55-64	413	31,989	1.29% (1.17% , 1.42%)	1.29% (1.15% , 1.45%)
	65+	382	43,449	0.88% (0.80% , 0.97%)	0.93% (0.82% , 1.05%)
Region	South East	578	39,156	1.48% (1.36% , 1.60%)	1.61% (1.46% , 1.77%)
	North East	62	5,731	1.08% (0.84% , 1.38%)	1.22% (0.87% , 1.69%)
	North West	220	17,917	1.23% (1.08% , 1.40%)	1.38% (1.16% , 1.64%)
	Yorkshire and The Humber	93	10,665	0.87% (0.71% , 1.07%)	0.80% (0.62% , 1.03%)
	East Midlands	225	21,698	1.04% (0.91% , 1.18%)	1.16% (0.99% , 1.36%)
	West Midlands	198	15,088	1.31% (1.14% , 1.51%)	1.66% (1.32% , 2.10%)
	East of England	391	25,178	1.55% (1.41% , 1.71%)	1.78% (1.57% , 2.02%)
	London	390	15,641	2.49% (2.26% , 2.75%)	2.83% (2.53% , 3.16%)
	South West	125	16,568	0.75% (0.63% , 0.90%)	0.87% (0.71% , 1.08%)
Employment type	Health care or care home worker	161	8,259	1.95% (1.67% , 2.27%)	2.24% (1.84% , 2.72%)
	Other essential/key worker	531	30,239	1.76% (1.61% , 1.91%)	1.79% (1.61% , 2.00%)
	Other worker	867	64,772	1.34% (1.25% , 1.43%)	1.55% (1.42% , 1.70%)
	Not full-time, part-time, or self-employed	670	60,438	1.11% (1.03% , 1.20%)	1.36% (1.23% , 1.50%)
	NA	53	3,934	1.35% (1.03% , 1.76%)	1.58% (1.10% , 2.27%)
Ethnic group	White	1938	152,111	1.27% (1.22% , 1.33%)	1.41% (1.33% , 1.49%)
	Asian	163	6,537	2.49% (2.14% , 2.90%)	2.80% (2.32% , 3.37%)
	Black	60	1,832	3.28% (2.55% , 4.19%)	3.07% (2.29% , 4.09%)
	Mixed	46	2,751	1.67% (1.26% , 2.22%)	1.78% (1.28% , 2.46%)
	Other	29	1,190	2.44% (1.70% , 3.48%)	2.42% (1.59% , 3.65%)
	NA	46	3,221	1.43% (1.07% , 1.90%)	1.76% (1.23% , 2.50%)
Household size	1	275	25,360	1.08% (0.96% , 1.22%)	1.24% (1.06% , 1.44%)
	2	622	61,379	1.01% (0.94% , 1.10%)	1.11% (1.01% , 1.23%)
	3	455	29,965	1.52% (1.39% , 1.66%)	1.67% (1.49% , 1.88%)
	4	568	34,847	1.63% (1.50% , 1.77%)	1.77% (1.59% , 1.96%)
	5	246	11,566	2.13% (1.88% , 2.41%)	2.48% (2.05% , 3.00%)
	6	79	3,196	2.47% (1.99% , 3.07%)	2.98% (2.26% , 3.93%)
	7+	37	1,329	2.78% (2.03% , 3.81%)	3.05% (2.04% , 4.56%)
COVID case contact	No	1130	138,065	0.82% (0.77% , 0.87%)	0.94% (0.87% , 1.02%)
	Yes, contact with a confirmed/tested COVID-19 case	730	5,008	14.58% (13.63% , 15.58%)	15.61% (14.26% , 17.06%)
	Yes, contact with a suspected COVID-19 case	58	1,329	4.36% (3.39% , 5.60%)	4.94% (3.57% , 6.79%)
	NA	364	23,240	1.57% (1.41% , 1.73%)	1.64% (1.45% , 1.87%)
Symptom status	Classic COVID symptoms	822	6,475	12.70% (11.91% , 13.53%)	14.05% (12.89% , 15.30%)
	Other symptoms	350	19,609	1.78% (1.61% , 1.98%)	1.89% (1.66% , 2.15%)
	No symptoms	747	118,401	0.63% (0.59% , 0.68%)	0.76% (0.68% , 0.84%)
	NA	363	23,157	1.57% (1.42% , 1.74%)	1.65% (1.45% , 1.87%)
Deprivation	1 Most deprived	257	15,190	1.69% (1.50% , 1.91%)	1.79% (1.53% , 2.10%)
	2	449	26,012	1.73% (1.57% , 1.89%)	1.95% (1.74% , 2.19%)
	3	479	36,061	1.33% (1.22% , 1.45%)	1.52% (1.36% , 1.69%)
	4	540	42,002	1.29% (1.18% , 1.40%)	1.41% (1.27% , 1.56%)
	5 Least deprived	557	48,377	1.15% (1.06% , 1.25%)	1.22% (1.10% , 1.35%)

Table 5. Jointly adjusted odds ratios for swab-positivity by: gender, age, region, key worker status, ethnicity, household size and index of area deprivation.

Variable	Category	Round 8
Gender	Male	Ref
	Female	0.95 [0.87,1.03]
Age Group	5-12	0.94 [0.78,1.15]
	13-17	1.70 [1.36,2.12]
	18-24	1.71 [1.40,2.09]
	25-34	1.30 [1.10,1.54]
	35-44	Ref
	45-54	1.15 [0.99,1.34]
	55-64	1.19 [1.02,1.39]
	65+	1.02 [0.85,1.22]
Region	North East	0.70 [0.54,0.92]
	North West	0.78 [0.66,0.92]
	Yorkshire	0.60 [0.48,0.75]
	East Midlands	0.69 [0.59,0.81]
	West Midlands	0.86 [0.73,1.02]
	East of England	1.01 [0.89,1.16]
	London	1.47 [1.27,1.69]
	South East	Ref
	South West	0.51 [0.42,0.62]
Key Worker Status	HCW/CHW	1.48 [1.25,1.77]
	Key worker (other)	1.35 [1.20,1.51]
	Other worker	Ref
	Not FT, PT, SE	0.90 [0.80,1.02]
Ethnicity	Asian	1.35 [1.14,1.61]
	Black	1.63 [1.24,2.14]
	Mixed	1.03 [0.77,1.39]
	Other	1.39 [0.96,2.03]
	White	Ref
Household Size	1-2 People	Ref
	3-5 People	1.37 [1.24,1.52]
	6+ People	2.02 [1.64,2.50]
Deprivation Index Quintile	1 - Most Deprived	Ref
	2	1.03 [0.88,1.21]
	3	0.82 [0.70,0.97]
	4	0.82 [0.70,0.96]
	5 - Least Deprived	0.72 [0.61,0.84]




Figure 1. Constant growth rate model fit to REACT-1 data for England for round 8. Shaded area shows the central 95% posterior credible interval.




Figure 2. Prevalence of national swab-positivity for England estimated using a p-spline fit to all 8 rounds of data (only shown for duration of latest round) with central 50% (dark grey) and 95% (light grey) posterior credible intervals. Points show daily estimated unweighted prevalence with vertical solid lines showing 95% confidence intervals. Vertical dashed lines show the official start of round 8 and the last day of data included in the round 8a analyses.




Figure 3. Facebook mobility data for England (black line) and the REACT-1 rounds (blue shaded regions). Baseline for mobility data is the mean movement during the week 10th - 16th March 2020 inclusive.




Figure 4. Prevalence of swab-positivity for each region of England estimated using a p-spline (with a constant second-order random walk prior distribution) fit to all 8 rounds of data (only shown for the duration of round 8) with central 50% (dark grey) and 95% (light grey) posterior credible intervals. Points show daily estimated unweighted prevalence with vertical solid lines showing 95% confidence intervals.




Figure 5. Regional comparison of REACT-1 estimated prevalence using a p-spline with central 50% (dark grey, left axis) and 95% (light grey, left axis) posterior credible intervals and routine PCR positivity for England (red, right axis) averaged over 7 days, plotted at the midpoint of the interval.




Figure 6. A Prevalence of national swab-positivity for England for rounds 7 and 8 of REACT-1 estimated using a p-spline for with central 50% (dark grey, red) and 95% (light grey, red) posterior credible intervals. **B** as A, but with posterior distribution filtered to keep only prevalence trajectories consistent with the Office for National Statistics Coronavirus Survey estimated prevalence of 2.06% in the last 5 days of December. Vertical dashed lines show the official start of round 8 and the last day of data included in the round 8a analyses.




Figure 7. Weighted prevalence of swab-positivity by region for round 8. Bars show 95% confidence intervals.




Figure 8. Weighted prevalence of swab-positivity by age group and region for round 8. Bars show 95% confidence intervals.




Figure 9. Weighted prevalence of swab-positivity by age group for round 8. Bars show 95% confidence intervals.




Figure 10. Estimated odds ratios and 95% confidence intervals for mutually-adjusted logistic regression model of swab-positivity for round 8. Models were adjusted for gender, age group, region, key worker status, ethnicity, household size, and deprivation index. The deprivation index is based on the Index of Multiple Deprivation (2019) at lower super output area. Here we group scores into quintiles, where 1 = most deprived and 5 = least deprived. HCW/CHW = healthcare or care home workers; Not FT, PT, SE = Not full-time, part-time, or self-employed. *Yorkshire and The Humber.




Figure 11. Neighbourhood prevalence of swab-positivity for round 8. Neighbourhood prevalence calculated from nearest neighbours (the median number of neighbours within 30km in the study). Average neighbourhood prevalence displayed for individual lower-tier local authorities. Regions: NE = North East, NW = North West, YH = Yorkshire and The Humber, EM = East Midlands, WM = West Midlands, EE = East of England, L = London, SE = South East, SW = South West. Data for unweighted point estimate of prevalence available in the supplementary data file.